The FDA just fast-tracked psychedelic drugs to treat depression. They could be here by this summer

The Trump administration is putting America on the fast track to a good trip. On Friday, April 24, the FDA granted an expedited review process to three experimental psychedelic drugs. It issued priority vouchers to three currently unnamed companies, two of which are expected to research psilocybin as a treatment for depression, and one which will study a drug called methylone, a stimulant similar to MDMA, for treating PTSD. Those vouchers shorten the FDA’s review process from its standard...